Korean J Clin Pharm.  2024 Mar;34(1):1-20. 10.24304/kjcp.2024.34.1.1.

Review of Efficacy and Safety of Semaglutide in the Management of Obesity

• Han S
• Park TE

• KMID: 2564357
• DOI: http://doi.org/10.24304/kjcp.2024.34.1.1

Abstract

This review examines the pivotal clinical trials that evaluated the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in the management of obesity. The reported findings underscore significant and sustained weight loss achieved with semaglutide in diverse patient groups, although gastrointestinal disorders occurred frequently, leading to therapy discontinuation. Overall, the studies demonstrated the potential of semaglutide as a therapeutic option not only for type 2 diabe- tes but also for obesity. The treatment landscape in obesity is evolving, as reflected in changing regulatory approvals and clinical guidelines, suggesting a paradigm shift toward personalized approaches in this chronic disease states to achieve optimal treatment outcomes for patients.

Keyword

GLP-1 receptor agonist; obesity; semaglutide; type 2 diabetes